From: How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?
Notation | Description | Value used | References |
---|---|---|---|
δ _{ D} | Diffusion coefficient of DCs | 8.64×10^{−7}cm^{2}day^{−1} | [59] |
δ _{ T} | Diffusion coefficient of T cells | 8.64×10^{−7}cm^{2}day^{−1} | [59] |
δ _{ E} | Diffusion coefficient of endothelial cells | 8.64×10^{−7}cm^{2}day^{−1} | [59] |
δ _{ C} | Diffusion coefficient of tumor cells | 8.64×10^{−7}cm^{2}day^{−1} | [59] |
\(\delta _{I_{12}}\) | Diffusion coefficient of IL-12 | 6.05×10^{−2}cm^{2}day^{−1} | [15] |
\(\delta _{I_{2}}\) | Diffusion coefficient of IL-2 | 9.58×10^{−2}cm^{2}day^{−1} | [15] |
\(\delta _{T_{\beta }}\) | Diffusion coefficient of TGF-β | 8.52×10^{−2}cm^{2}day^{−1} | [15] |
δ _{ W} | Diffusion coefficient of oxygen | 0.8 cm^{2}day^{−1} | Estimated |
δ _{ G} | Diffusion coefficient of VEGF | 8.64×10^{−2}cm^{2} day^{−1} | [57] |
δ _{ A} | Diffusion coefficient of anti-PD-L1 | 4.73×10^{−2}cm^{2}day^{−1} | [15] |
δ _{ B} | Diffusion coefficient of anit-VGEF | 4.70×10^{−2}cm^{2}day^{−1} | Estimated |
σ _{ T} | Flux rate of T_{1} and T_{8} cells at the boundary | 1 cm^{−1} | [59] |
σ _{ E} | Flux rate of T_{1} and T_{8} cells at the boundary | 1 cm^{−1} | [59] |
χ _{ G} | Chemoattraction coefficient of VEGF | 10 cm^{5}/g·day | [64, 65] |
λ _{ DC} | Activation rate of DCs by tumor cells (mice) | 17.5day | Estimated |
λ _{ DC} | Activation rate of DCs by tumor cells (humans) | 7.5day | Estimated |
\(\lambda _{T_{1}I_{12}}\) | Activation rate of CD 4^{+} T cells by IL-12 | 11.65 day^{−1} | Estimated |
\(\lambda _{T_{1}I_{2}}\) | Activation rate of CD 4^{+} T cells by IL-2 | 0.25 day^{−1} | [59] |
\(\lambda _{T_{8}I_{12}}\) | Activation rate of CD 8^{+} T cells by IL-12 | 10.38 day^{−1} | Estimated |
\(\lambda _{T_{8}I_{2}}\) | Activation rate of CD 8^{+} T cells by IL-2 | 0.25 day^{−1} | [59] |
\(\lambda _{T_{r}T_{\beta }}\) | Activation rate of Tregs by TGF-β | 0.415 day^{−1} | Estimated |
\(\lambda _{T_{r}G}\) | Activation rate of Tregs by VEGF | 0.083 day^{−1} | Estimated |
λ _{ E} | Growth rate of endothelial cells (mice) | 2.77×10^{7}cm^{3}/g·day | Estimated |
λ _{ E} | Growth rate of endothelial cells (humans) | 2.08×10^{7}cm^{3}/g·day | Estimated |
λ _{ CW} | Growth rate of cancer cells (mice) | 2.24 day^{−1} | Estimated |
λ _{ CW} | Growth rate of cancer cells (humans) | 1.76 day^{−1} | Estimated |
\(\lambda _{I_{12}D}\) | Production rate of IL-12 by DCs | 2.21×10^{−6}day^{−1} | [15] |
\(\lambda _{I_{2}T_{1}}\) | Production rate of IL-2 by CD 4^{+} T cells | 2.82×10^{−8}day^{−1} | [15] |
\(\lambda _{T_{\beta } C}\) | Production rate of TGF-β by cancer cells | 3.27×10^{−10}day^{−1} | Estimated |
\(\lambda _{T_{\beta } T_{r}}\) | Production rate of TGF-β by Tregs | 5.57×10^{−9}day^{−1} | [61] |
λ _{ WE} | Production rate of oxygen by endothelial cells | 7×10^{−2}/day | [43] |
λ _{ GW} | Production rate of VEGF by cancer cells | 2.21×10^{−6}day^{−1} | Estimated |
ε _{ T} | Relative expression of PD-1 in Tregs | 0.8 | [15] |
ε _{ C} | Relative expression of PD-L1 in tumor cells | 0.01 | [15] |
ε _{ G} | Relative rate of PD-1 promotion by VEGF | 1.43×10^{6}cm^{3}/g | Estimated |